Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01815632
Other study ID # ACTiMuS
Secondary ID ISRCTN27232902
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 2014
Est. completion date October 2019

Study information

Verified date June 2018
Source North Bristol NHS Trust
Contact Claire M Rice, MA MRCP PhD
Phone 00 44 117 4146695
Email claire.rice@nbt.nhs.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multiple sclerosis - MS - affects 1.3m people worldwide, costing the European Union economy €9 billion/year, through both direct and indirect consequences of progressive disability. Despite the usual relapsing-remitting presentation, over 80% of patients develop progressive disability; 40% require a wheelchair within 10 years of diagnosis. At present, there are no treatments that reverse, halt or even slow progressive disability in MS.

The investigators recently completed one of the first feasibility/safety trials in the world of reparative bone marrow cell therapy in 6 patients with longstanding MS (www.nature.com/clpt/journal/v87/n6/full/clpt201044a.html). Safety was confirmed, and intensive repeated tests on the patients measuring nerve conduction in various pathways in the brain and in the spinal cord showed statistically significant improvements at 12 months in every patient. While highly preliminary and involving only a very small number of patients, these results at least raise the possibility of a significant (though very partial) underlying repair effect within the damaged nervous system.

The investigators believe this urgently requires further testing - both to accelerate benefit for patients, and to begin improving therapeutic efficacy. The investigators therefore propose a programme of translational and clinical stem cell research, aiming (1) to continue translation with a phase two controlled trial of bone marrow cells in patients with longstanding MS; and (2) to explore in parallel the potential mechanisms of action, by studying bone marrow cells from treated patients and control subjects, aiming to establish which of the various relevant bone marrow subpopulations contribute to efficacy, and which particular reparative mechanism(s) are important. The investigators hope these studies will not only confirm the therapeutic benefit of this approach, but also provide the basis for improving the magnitude and impact of this novel and exciting treatment modality.


Description:

The primary objective is to determine whether autologous bone marrow (BM) (ie taken from the patients themselves rather than from a BM donor) cell therapy is truly beneficial in chronic multiple sclerosis - as our small, uncontrolled phase 1 trial suggested (www.nature.com/clpt/journal/v87/n6/full/clpt201044a.html).

The investigators also aim to answer the following questions:

1. Do BM mesenchymal stem cells from patients with MS differ in the range or extent of reparative and neuroprotective properties from those from control individuals?

2. What reparative and neuroprotective properties do BM stem cell subpopulations other than mesenchymal stem cells possess, and do these differ between MS patients and controls?

3. Can BM stem cell subpopulations be isolated from blood samples from MS patients following treatment, and, if so, for how long?

Bone marrow contains stem cells capable of replacing all the cells in the blood. Recently, bone marrow has been found to contain cells capable of replacing cells in tissues and organs other than blood. In addition, infusion of bone marrow-derived cells has been shown to have significant effects on the immune system and to promote the survival of central nervous system cells under toxic conditions. These properties are of considerable interest to those working to develop cell-based therapies for neurodegenerative disease.

The potential of such cells to aid repair in multiple sclerosis (MS) has been examined in experimental models of MS. Myelin is the substance that insulates neurons within the central nervous system and is attacked in MS. Infusion of adult bone marrow cells into a vein aids myelin repair (remyelination) in these models of MS. Recently, the investigators performed a small pilot study to examine the effects of harvesting bone marrow from MS patients and infusing this back into each patient's vein. This was well tolerated and no significant adverse events were encountered. Electrophysiological studies appeared to show some improvement but, given the small numbers of participants in the phase 1 trial, no definitive conclusion can be made regarding this.

The current study seeks to address the question of whether genuine improvements in neurophysiological tests are seen in MS patients with progressive disease following infusion of bone marrow.

A prospective, randomised, double-blind, placebo-controlled, stepped wedge design will be employed at a single centre (Bristol, UK). Eighty patients with progressive MS will be recruited; 60 will have secondary progressive disease (SPMS) but a subset (n=20) will have primary progressive disease (PPMS). Participants will be randomised to either early (immediate) or late (1 year) intravenous infusion of autologous, unfractionated bone marrow. The placebo intervention is infusion of autologous blood. The primary outcome measure is global evoked potential derived from multimodal evoked potentials. Secondary outcome measures include adverse event reporting, clinical (EDSS and MSFC) and self-assessment (MSIS-29) rating scales, optical coherence tomography (OCT) as well as brain and spine MRI. Participants will be followed up for a further year following the final intervention. Outcomes will be analyzed on an intention-to-treat basis.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date October 2019
Est. primary completion date October 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Diagnosis of clinically-definite MS as defined by the McDonald criteria

- Aged 18 - 65 years.

- EDSS of 4.0 to 6 inclusive

- Disease duration >5 years

- Disease progression (increase in physical disability, not due to major relapse) in preceding year

- Signed, written informed consent

- Willing and able to comply with study visits according to protocol for the full study period

Exclusion Criteria:

- Pregnancy, breastfeeding or lactation

- History of autologous/allogenic bone marrow transplantation or peripheral blood stem cell transplant

- Bone marrow insufficiency

- History of lymphoproliferative disease or previous total lymphoid irradiation

- Immune deficiency

- Current or recent (<5 years) malignancy

- Chronic or frequent drug-resistant bacterial infections or presence of active infection requiring antimicrobial treatment

- Frequent and/or serious viral infection

- Systemic or invasive fungal disease within 2 years of entry to study

- Significant renal, hepatic, cardiac or respiratory dysfunction

- Contraindication to anaesthesia

- Bleeding or clotting diathesis

- Current or recent (within preceding 12 months) immunomodulatory therapy other than corticosteroid therapy

- Treatment with corticosteroids within the preceding three months

- Significant relapse within preceding 6 months

- Predominantly relapsing-remitting disease over preceding 12 months

- Radiation exposure in the past year other than chest / dental x-rays

- Previous claustrophobia

- The presence of any implanted metal or other contraindication to MRI

- Participation in another experimental study or treatment within the preceding 24 months

Study Design


Intervention

Other:
Early infusion of autologous marrow
Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
Late infusion of autologous marrow
Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.

Locations

Country Name City State
United Kingdom Southmead Hospital Bristol

Sponsors (11)

Lead Sponsor Collaborator
North Bristol NHS Trust Bristol Royal Hospital for Children, Catholic Bishops of England and Wales, Friends of Frenchay, Kenneth and Claudia Silverman Family Foundation, Medical Research Council, Multiple Sclerosis Trust, NHS Blood and Transplant, Rosetrees Trust, University of Bristol, University of Nottingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Global evoked potential (GEP): mean change from time of marrow infusion to end of study Multimodal evoked potentials will be examined at 0, 6, 12, 18 and 24 months. Evoked potential abnormalities will be quantified according to a 4-point graded ordinal score modified from Leocani et al (JNNP 2006, 77:1030-1035) (0=normal; 1=increased latency; 2=increased latency and abnormal amplitude; 3=absent).
The recording of the evoked potentials shall be in accordance with the Guidelines of the International Federation of Clinical Neurophysiology and analysis will be performed using standard methods. Electrophysiological responses shall be considered abnormal if they exceed 2.5 standard deviations of the normal values or cannot be detected.
Entry and every 6 months for 2 years
Secondary Safety Evaluation of number and nature of adverse events Continuous throughout study period (2 years)
Secondary Expanded disability status scale Time to EDSS progression of at least one point from a baseline EDSS of 4.0, 4.5 or 5.0 or at least 0.5 points from a baseline EDSS =5.5 At entry then 6 weeks, 6 months and 1 year after each infusion
Secondary Multiple sclerosis impact scale (MSIS-29) Mean change from baseline to end of study on the patient-based MSIS-29 scale At entry then 6 weeks, 6 months and 1 year after each infusion
Secondary Multiple sclerosis functional composite (MSFC) Mean change on MSFC score from baseline to final visit At entry then 6 weeks, 6 months and 1 year after each infusion
Secondary MRI head and cord The secondary MRI outcome measures will relate to 1) lesion load, 2) atrophy measures both of the brain and of cross-sectional area of the spinal cord, and changes in mean diffusivity.
Exploratory analysis of the resting-state fMRI data will investigate correlations between network patterns and 'strength' of networks connectivity from the resting-state fMRI with classifications revealed by the various evoked potential studies
At entry, 1 year and 2 years post-harvest
Secondary Optical coherence tomography Measurement of retinal nerve fibre layer thickness and macular volume Entry, 1 year and 2 years post-harvest
See also
  Status Clinical Trial Phase
Completed NCT02282826 - A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis Phase 1
Completed NCT02804594 - A Study of Oxidative Pathways in MS Fatigue Phase 2
Completed NCT04120675 - Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis N/A
Completed NCT01719159 - Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis Phase 2
Enrolling by invitation NCT03552211 - Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
Recruiting NCT05740722 - Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis Phase 2
Completed NCT03980145 - G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis N/A
Completed NCT03269071 - Neural Stem Cell Transplantation in Multiple Sclerosis Patients Phase 1
Not yet recruiting NCT05811013 - Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis N/A
Not yet recruiting NCT04289909 - Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS) N/A
Recruiting NCT05685784 - Multiple Sclerosis Prediction and Monitoring of Progression Study N/A
Completed NCT03493841 - Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis Phase 1
Completed NCT03302806 - Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
Recruiting NCT05441488 - Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis Phase 3
Recruiting NCT04695080 - ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis Phase 2/Phase 3
Recruiting NCT06451159 - A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis Phase 1
Completed NCT03423121 - A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis Phase 1/Phase 2
Terminated NCT02580669 - Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis N/A
Enrolling by invitation NCT05706220 - Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
Recruiting NCT01364246 - Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Phase 1/Phase 2